Pete Knox

/Pete Knox

About Pete Knox

This author has not yet filled in any details.
So far Pete Knox has created 22 blog entries.

Quadruple-Negative GIST Tumors May Be More Likely To Harbor NF1 Mutations As Well

In a pre-print electronic publication of the July 7, 2016 edition of Clinical Cancer Research, a team of Italian researchers examined the link between “Quadruple-Negative” GISTs (those that do not exhibit KIT, PDGFRA, or BRAF [...]

By | 2018-08-01T11:55:43+00:00 July 19th, 2016|Clinical Trials, News, Research|

Ignyta Announces Results for Potential New Cancer Treatment

Dr. Alexander Drilon of Memorial Sloan Kettering Cancer Center recently reported at AACR on a potential new cancer treatment, Entrectinib, a receptor tyrosine kinase (RTK) inhibitor developed to target tumors carrying NTRK1, NTRK2, NTRK3, ROS1, [...]

By | 2018-08-01T11:51:21+00:00 July 12th, 2016|Clinical Trials, News, Research|

Update on Blueprint Medicines Clinical Trial for BLU-285

Recently a number of companies have begun to develop therapeutic options that target some of the rarer mutations in GIST. As there are currently no approved treatments specifically for these patients, this [...]

By | 2018-06-12T11:25:27+00:00 May 24th, 2016|Clinical Trials, News, Research|

Genetic Alliance event invites collaboration

Genetic Alliance recently held an event in Chapel Hill, N.C. that brought together patient advocates, scientists and representatives from the pharmaceutical industry in a unique “speed-dating” format. Disease advocacy organizations were invited to present briefly [...]

By | 2015-12-16T13:44:30+00:00 December 16th, 2015|Advocacy, Newsletter|

Adjuvant imatinib study updates results

A recent study further documented the advantage of three years of adjuvant imatinib versus one year in high-risk GIST patients. The study, which is to be published in the Journal of Clinical Oncology, was authored by [...]

By | 2016-03-15T14:14:11+00:00 December 16th, 2015|Gleevec, News, Newsletter, Research, Survival Strategies|

Conditional Disease-free Survival after GIST Resection Improves Over Time

In a recent study led by Danielle A Bischof, MD of Johns Hopkins and published in JAMA Surgery, the authors propose a new way of estimating disease-free survival for GIST patients – Conditional Disease-free Survival [...]

By | 2015-03-20T12:52:42+00:00 March 24th, 2015|News, Risk Assessment|

Life Fest 2014: What’s New in the Science of GIST?

In addition to spending time catching up with fellow patients and caregivers and attending the myriad of useful workshops featured at Life Fest 2014, participants were treated to an update of what is new in [...]

By | 2018-07-26T12:21:11+00:00 December 8th, 2014|GIST Education, News, Research|

Expert patient training program a success

The LRG is proud to announce that the inaugural class of our GIST Expert Patient Training Program has been completed. The class, which was open to GIST patients, caregivers, and other members oaf the extended GIST community, was comprised of just under 20 students and was a comprehensive offering designed to help participants better understand the science behind GIST.

By | 2014-07-02T12:36:29+00:00 July 2nd, 2014|GIST Education, News|

Recent Posts

Upcoming Events

  1. Sarcoma & GIST: Education Symposium

    September 29 @ 9:00 AM - 2:45 PM
  2. Michigan GDOL 2018

    Michigan GDOL 2018

    October 27 @ 8:00 AM - 3:00 PM
  3. NTFC

    Night to Fight Cancer

    November 7 @ 6:00 PM - 11:00 PM